What King-Devick technologies does

King-Devick Technologies, Inc. is a privately held medical technology company that develops evidence-based, FDA-cleared eye movement (oculomotor) assessment tools primarily for rapid sideline concussion screening and broader neurological and visual function monitoring. Founded in 2010 and headquartered in Oak Brook, Illinois, the company's portfolio is anchored by the King-Devick Test (KDT) — a two-minute rapid number-naming assessment for saccadic eye movement evaluation that carries FDA pre-amendment certification and is co-branded with Mayo Clinic under a 2015 equity partnership. The product suite spans three categories: Sideline Assessment (KDT and the FDA 510(k)-cleared K-D Balance vestibular app), Reading Solutions (K-D RAP, K-D Test Pro Reading, KD4KiDs), and Neurological Function (K-D Test Pro Monitoring, K-D Eye Tracking Software, the MiHED migraine early-detection app, and the K-D Variable Color Contrast Sensitivity Acuity Chart).

The technical foundation combines rapid number-naming methodology with automated speech recognition (ASR) to objectively quantify saccadic eye movements, attention, and language function, with results compared against age-related normative databases. The KDT is validated in over 200 peer-reviewed studies showing 86% sensitivity and 90% specificity for concussion detection, and the technology holds patents-pending status. International regulatory footprint extends to Health Canada medical device licensure, EU Class I Medical Device registration, and Australia TGA registration.

The company operates a hybrid B2B/B2C model: enterprise field sales to U.S. professional sports leagues (NHL, NFL, NASCAR, MLL, CFL, NWHL, AHL) and major NCAA Division I programs (Ohio State, Miami, Florida, Penn, Washington, Idaho), combined with direct-to-consumer distribution via its own e-commerce storefront and iOS/Android app stores. Pricing spans per-athlete annual licenses ($10-$20), annual per-license clinical monitoring ($44.20-$52), one-time reading packages ($200 for 20 screenings, $650 for 10 activations), and a monthly MiHED consumer subscription at $799. Founder Dr. Steve Devick, OD leads as CEO and Chairman, with COO Samantha Figueroa, CTO Richard Cronin, and a Board including Mayo Clinic neurologist Dr. David W. Dodick; the company has disclosed no external institutional funding rounds.

Name

King-Devick technologies

Legal name

King-Devick technologies, Inc.

Website

https://kingdevicktest.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

King-Devick Technologies develops FDA-cleared, evidence-based oculomotor assessment tools — primarily the King-Devick Test for rapid sideline concussion screening — for professional and collegiate sports organizations, schools, healthcare providers, military/VA, and consumers across the U.S., Canada, EU, and Australia.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827)

akta.pro primary industry

Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)

akta.pro secondary industries

Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment) (HLAHAJAM), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

Keywords

• Concussion screening software
• Eye movement assessment
• Oculomotor rehabilitation
• Vestibular balance testing
• Reading acceleration programs

Headquarters

HQ city

Oak Brook

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Medical Device Sales (Concussion Screening): One-time and annual license sales of King-Devick Test products for concussion assessment. Volume pricing for organizations with 100+ athletes. Minimum order of 3 athletes.
2. Clinical Monitoring Software: Annual licenses for K-D Test Pro Monitoring with quantity discounts (5-15% off for 15+ licenses). Per-license pricing ranging from $52 to $44.20 based on volume.
3. Clinical Reading Solutions: K-D Test Pro Reading sold at $200 for 20 screenings. K-D RAP at $650 for 10 patient activations.
4. Recovery Acceleration Program: Annual licenses for oculomotor rehabilitation program. Subject licenses sold in bundles of 10 at $650.
5. Migraine Detection Subscription: Monthly subscription at $799/month for MiHED app providing unlimited annual testing per individual.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

King-Devick technologies develops and sells FDA-cleared medical software and mobile applications for rapid saccadic eye movement assessment, concussion detection, vestibular balance evaluation, oculomotor-based reading improvement, and neurological function monitoring. Its portfolio includes the flagship King-Devick Test (co-branded with Mayo Clinic), K-D Balance, K-D Reading Acceleration Program (K-D RAP), MiHED migraine early-detection app, K-D Eye Tracking, K-D Recovery Acceleration Program, and clinical reading/monitoring tools used by professional sports leagues, schools, healthcare providers, and the U.S. military.

Product overview

King-Devick technologies offers an evidence-based suite of eye movement assessment and rehabilitation tools. The core portfolio centers on the FDA pre-amendment certified King-Devick Test in association with Mayo Clinic for concussion screening, complemented by FDA 510(k) cleared K-D Balance for vestibular assessment. The Reading Solutions division includes the K-D Reading Acceleration Program for improving reading fluency in children, K-D Test Pro Reading for clinical screenings, and KD4KiDs for home reading practice. Neurological Function products include K-D Test Pro Monitoring for progress tracking, K-D Eye Tracking Software for detailed oculomotor analysis, MiHED for migraine early detection, and the K-D Variable Color Contrast Sensitivity Acuity Chart for visual assessment. All products leverage rapid number naming technology and automated speech recognition to objectively measure saccadic eye movements and cognitive function.

Differentiator

Problem solved

Functional benefit

Products and services

• King-Devick Test in association with Mayo Clinic (KDT) A two-minute rapid number naming assessment for concussion detection. Individuals read aloud single-digit numbers from a card or screen, evaluating impairments of eye movements (saccades), attention, and language function. FDA pre-amendment certified for assessment of saccadic eye movements. Used by sports organizations, schools, military, and healthcare providers.
• K-D Balance FDA 510(k) cleared mobile application for vestibular dysfunction assessment. Measures three balance stance metrics — double stance, right tandem stance, and left tandem stance — using the iPhone/iPod Touch internal accelerometer. Used by clinicians and sideline medical staff.
• K-D Reading Acceleration Program (K-D RAP) An oculomotor rehabilitation program that teaches early readers to move their eyes accurately and efficiently while reading. Improves oral reading fluency and comprehension in elementary students; delivered in at-home, at-school, and in-office editions.
• K-D Test Pro Reading iPad-based clinical vision screening program for identifying reading-related eye movement disorders. Automatically compares test results with age-related normative data for patients aged 6–14+ years. Used in clinical and school settings.
• K-D Test Pro Monitoring Clinical monitoring software that objectively and quantitatively tracks King-Devick Test progress with charts and graphs for serial monitoring of saccadic impairment in patients over 15 years old.
• K-D Eye Tracking Software System Quantitative eye tracking system providing detailed assessment of oculomotor function during K-D Test performance. Visualizes raw scan paths with fixations and saccades, quantifying impairment severity and recovery progression.
• King-Devick Migraine Headache Early Detection (MiHED) iPad application designed for individuals with migraine history to detect the prodrome (pre-headache) phase of migraine attacks, often 1–6 hours prior to headache onset. Uses automated speech recognition to analyze K-D Test performance.
• King-Devick Variable Color Contrast Sensitivity Acuity Chart (VCCSAC) Tablet-based software for assessment of visual acuity, contrast sensitivity, and color vision. Displays Sloan letter sizes in Snellen and M units with variable contrast levels (100, 75, 2.5, and 1.25%) and primary colors (red, green, blue, yellow).
• K-D Recovery Acceleration Program (K-D RAP Recovery) Web-based oculomotor rehabilitation program for subjects suffering from eye movement deficits following brain injury. Includes compliance monitoring, goal-setting, and individual program tailoring with real-time outcome measures.
• KD4KiDs E-book application for practicing the physical act of reading with children, part of the King-Devick reading solutions portfolio for at-home use.

Quantifiable outcome

• 86% sensitivity and 90% specificity for concussion detection (meta-analysis)
• +5 more outcomes

Named customers12 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

One partnership is on record.

• Mayo ClinicflagshipStrategic or Co-development Partner · 1 January 2015In 2015, Mayo Clinic executed its first co-branding equity contract in its 150-year history with King-Devick Technologies. King-Devick's proprietary sideline concussion screening product was renamed as the King-Devick Test in association with Mayo Clinic. This partnership provides significant medical credibility and co-marketing opportunity.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• ImPACT Applications: ImPACT Applications is the dominant computerized concussion assessment tool used widely by the NFL, NCAA, and high schools. It is the most direct competitor to the King-Devick Test for sideline concussion screening, targeting the same athletic trainers, sports medicine physicians, and school districts.
• SyncThink: SyncThink develops eye-tracking-based concussion and neurological assessment technology (EVO platform) used by the Golden State Warriors, NCAA, and military. It competes directly with King-Devick's oculomotor-based concussion screening and eye tracking software, and serves a similar sports medicine and clinical neurology market.
• RightEye: RightEye offers eye-tracking and oculomotor assessment tools used for concussion, vision, and reading performance evaluation in clinical and sports settings. It overlaps directly with KDT's clinical oculomotor assessment and reading acceleration product lines, and serves a similar optometry and rehabilitation customer base.
• Oculogica: Oculogica is a neurodiagnostic company that uses eye-tracking biomarkers to detect concussions and TBI. It is a direct peer in the objective eye-movement-based concussion assessment category, with comparable FDA pathway ambitions and clinical validation approach.

Emerging players

• BrainScope: BrainScope develops FDA-cleared, non-invasive, AI-powered devices for objective assessment of traumatic brain injury, including concussion. It is an emerging competitor in the broader TBI assessment category KDT targets, particularly for emergency departments and military use cases where the company also sells.
• C3 Logix: C3 Logix provides a comprehensive concussion management platform combining balance, cognitive, and oculomotor testing for athletic organizations. It directly overlaps with KDT's K-D Balance and KDT sideline offerings, targeting similar high school and collegiate athletic programs.
• BRAINBox Solutions: BRAINBox Solutions is developing AI-enabled, multi-modality blood-based and clinical diagnostic tests for mild TBI/concussion. It is an emerging player in the same objective concussion assessment category as KDT, with similar ambitions to displace subjective sideline screening tools.
• NeuroCatch: NeuroCatch is a Health Canada-cleared, rapid neurophysiological device for objective concussion and cognitive assessment using event-related potentials. It targets similar sports medicine, military, and clinical concussion use cases as KDT, and represents an emerging objective brain-function assessment alternative.

Broad incumbents

• NeurOptics: NeurOptics is an established medical device company specializing in pupillometry and neurological assessment in critical care, ICU, and research settings. While not a direct concussion screening competitor, it operates in the adjacent neurological assessment and monitoring category and uses similar FDA-cleared medical device channels.

Others

• Mayo Clinic: Mayo Clinic is King-Devick's flagship co-branding equity partner and a major clinical validator. As a healthcare system partner and originator of clinical validation studies, Mayo functions as an ecosystem enabler—channeling research, clinical credibility, and federal/military referrals to KDT.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/kingdevicktest
• Facebookfacebook.com/kingdevicktest

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about King-Devick technologies